Apple Inc vs ARK Genomic Revolution ETF — how do they compare? Apple Inc trades at $302.06 (market cap $4.45T), while ARK Genomic Revolution ETF trades at $44.51. The key difference: Apple Inc pays a 0.35% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Apple Inc nearer its low. Which is the better fit depends on your goals.
| AAPL | ARKG | |
|---|---|---|
Market Cap | $4.45T | — |
Volume | 100,358,844 | — |
Sector | Technology | Sector/Thematic |
52-Week High | $340.08 | $44.55 |
52-Week Low | $224.90 | $24.02 |
Enterprise Value | $4.47T | — |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.14, down 2.31% on the day, with a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate. Revenue grew to $416.16B in 2025, and net income margin improved to 26.91%. However, valuation ratios like P/E of 34.97 and P/B of 41.39 appear elevated. Recent news highlights AI potential through its device ecosystem but also store closures and union disputes.
The outlook is mixed: solid fundamentals and analyst buy consensus support upside to the $337.63 price target, but high valuations and technical bearishness near-term pose risks. Key opportunities include AI integration and cash flow strength; risks involve competitive pressures, regulatory scrutiny, and execution on growth initiatives.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →